Effects of CBD on cognitive function in patients with schizophrenia
| Subjects; diagnosis | Study design | Dose of CBD; formulation | Measure of cognition | Cognitive outcome | Reference |
|---|---|---|---|---|---|
18 M, 10 F (> 18 years); DSM-IV schizophrenia | Randomised, double-blind, placebo-controlled, parallel group | 300 mg, 600 mg; gelatin capsules; matching placebo | SCWT | No beneficial effects of CBD as single dose | [37] |
51 M, 37 F (mean age 40.8 years); DSM-IV schizophrenia | Double-blind, placebo-controlled, parallel group | 1000 mg/day for 6 weeks; oral solution | BACS | BACS improved not significantly | [38] |
25 M, 11 F (18–65 years); DSM-IV schizophrenia or schizoaffective disorder | Double-blind, placebo-controlled, parallel group | 600 mg/day for 6 weeks; oral tablet | MATRICS | No significant effects on cognition | [39] |
32 M, 7 F (18–50 years); DSM-IV schizophrenia or schizophreniform psychosis | Double-blind, randomised, parallel group | Up to 800 mg/day for 4 weeks; oral tablet | Measures of pattern recognition, attention, working memory, verbal and visual memory, learning, processing speed, and verbal executive functions | No difference between CBD-treated and AMI-treated patients; improved function for visual memory, processing speed, sustained attention, and visuomotor coordination | [41] |
AMI: amisulpride; BACS: Brief Assessment of Cognition in Schizophrenia; MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia; F: female; M: male
